Helwig v. Vencor, Inc.

251 F.3d 540, 2001 U.S. App. LEXIS 11236, 2001 WL 578541
Court of Appeals for the Sixth Circuit·Decided May 31, 2001·No. No. 99-5153·Published·Cited by 212 cases

Opinions

MERRITT, J., delivered the opinion of the court, in which MARTIN, C. J., DAUGHTREY, MOORE, COLE, CLAY, and GILMAN, JJ„ joined. KENNEDY, J. (pp. 566-73), delivered a separate dissenting opinion, with BOGGS, NORRIS, SUHRHEINRICH, SILER, and BATCHELDER, JJ„ joining in Judge KENNEDY’S dissent.

OPINION

MERRITT, Circuit Judge.

The complaint in this securities class action features allegations of insider trading, fraudulent omissions, and inflated stock prices punctured by bad news in the health care industry. The principal issues on appeal arise under the new pleadings standard created by the Private Securities Litigation Reform Act of 1995. As often is the case in suits for securities fraud, we must deal with controverted inferences of knowledge and intent to defraud from facts that give rise to more than one interpretation. How to steer a course between indulging strike suits and predatory allegations on the one hand and deterring meritorious claims on the other: This has been the work of Congress and a number of our sister circuits. The fruit of their efforts has been a statute containing general language at a high level of abstraction, an ambiguous legislative history, and a triparted split among the circuit courts. We conclude that plaintiffs here have stated a claim for securities fraud by creating — in the words of the statute — a “strong inference” that defendants projected financial well-being at a time when they had actual knowledge that their statements were false or misleading, while knowingly omitting material facts that would have tempered their optimism. Accordingly, the judgment of the district court will be REVERSED and the case REMANDED for further proceedings.

An outline of our discussion of the issues is as follows:

I. Facts
II. The Private Securities Litigation Reform Act
A. The Safe Harbor
B. The Pleading Standard
[545] III. Plaintiffs’ Allegations Concerning the Effect of the Balanced Budget Act
A. Vencor’s Forward-Looking Statements
1. Materiality
2. Actual Knowledge of Misleading or False Nature
3. Not Identified as Forward Looking / Absence of Meaningful Cautionary Statements
B. Sufficiency of Plaintiffs’ Complaint
C. Response to the Dissent
IV. Other Claims
A. Vencor’s Acquisition of TheraTx
B. Vencor’s Acquisition of Transitional Hospitals Corporation
C. Vencor’s Proposed Sale of Behavioral Healthcare Corporation
V. Conclusion

I. FACTS

The factual allegations of this case are more fully described in section III of the opinion after a discussion of the pleading-standard to be applied under the new Act. We will recite only the most salient details here. At the time of the events in suit, defendant Vencor, a company then traded on the New York Stock Exchange, was said to be the largest full-service long-term health care provider in the United States, focusing on hospital and nursing services. Six of its directors are also named as defendants. Plaintiffs are a class of investors in Vencor. They allege a number of misstatements and material omissions by Vencor calculated to artificially balloon stock prices and defraud purchasers. A divided panel of this court concluded that plaintiffs failed to state a claim. Helwig v. Vencor, Inc., 210 F.3d 612 (6th Cir.2000). We granted plaintiffs’ petition for a rehearing en banc. Helwig v. Vencor, Inc., 222 F.3d 268 (6th Cir.2000). Because this case is, at root, about sufficiency of pleading, we will examine each of plaintiffs’ contentions in turn.

1. The Impact of the Balanced Budget Act — On February 6, 1997, President Clinton proposed the Balanced Budget Act (the “Budget Act”), which featured several Medicare provisions that would substantially affect the health care industry. Separate bills passed the House and Senate on June 25, 1997. This necessitated a conference report, which was filed on July 30. President Clinton signed the bill on August 5. See Balanced Budget Act of 1997, Pub.L. No. 105-33 (1997).

During this half-year of legislative deliberation, the proposed act alarmed sectors •of the health care industry because it changed Medicare reimbursement and reduced incentive payments for hospitals that kept actual costs below federal targets. Because Vencor derived significant revenue from Medicare, it too was concerned about several aspects of the proposed act and received regular updates from its lobbyists in Washington, D.C. Plaintiffs claim that the company undertook an analysis of the proposed act as early as April 1997. According to plaintiffs, these cost analyses culminated in July 1997 when Thomas Schumann, vice president and director of Vencor’s reimbursement department, circulated an internal memorandum detailing the potential impact of the legislation.

In the meantime-from at least February 10, 1997, until October 21, 1997' — defendants maintained that they were “comfortable” with projections of fourth-quarter earnings of $0.59 to $0.64 per share and yearly returns between $2.10 to $2.20 for 1997 and $2.60 to $2.65 for 1998. Such sanguine statements led market analysts to recommend Vencor’s stock as a “buy.” In its 1996 Form 10 K, filed March 27, [546]*5461997, the company did acknowledge the looming Budget Act:

[T]he Company cannot predict the content of any healthcare or budget reform legislation which may be proposed in Congress or in state legislatures in the future, and whether such legislation, if any, will be adopted. Accordingly, the Company is unable to assess the effect of any such legislation on its business. There can be no assurance that any such legislation will not have a material adverse impact on the Company’s future growth, revenues and income.

Other more cursory warnings later appeared in Vencor’s first- and second-quarter 10-Q forms, filed April 23 and July 25 respectively.

On October 22, 1997, Vencor lowered its estimates of fourth-quarter earnings due to “management’s recently completed analysis of the Balanced Budget Act of 1997.” The stock price dropped from $42-5/8 per share to $30 per share, a nearly thirty percent decline. Soon after, the company announced that an anticipated sale of one of its divisions would not be completed. The stock price fell further to $23 per share. Plaintiffs allege that Vencor knew about the likely adverse impact of the Budget Act before its October announcement but nonetheless made false and misleading earnings statements to boost stock prices.

Free access — add to your briefcase to read the full text and ask questions with AI

Helwig v. Vencor, Inc., 251 F.3d 540, 2001 U.S. App. LEXIS 11236, 2001 WL 578541 (6th Cir. 2001).

251 F.3d 540 (Helwig v. Vencor, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

In Re Harman International Industries, Inc. Securities Litigation
27 F. Supp. 3d 26 (District of Columbia, 2014)
In Re Regions Morgan Keegan Securities, Derivative
743 F. Supp. 2d 744 (W.D. Tennessee, 2010)
In Re Semgroup Energy Partners, L.P.
729 F. Supp. 2d 1276 (N.D. Oklahoma, 2010)
Konkol v. Diebold, Inc.
590 F.3d 390 (Sixth Circuit, 2009)
Lane v. Page
581 F. Supp. 2d 1094 (D. New Mexico, 2008)
In Re Huffy Corp. Securities Litigation
577 F. Supp. 2d 968 (S.D. Ohio, 2008)
In Re National Century Financial Enterprises, Inc.
580 F. Supp. 2d 630 (S.D. Ohio, 2008)
Grillo v. Tempur-Pedic International, Inc.
553 F. Supp. 2d 809 (E.D. Kentucky, 2008)
In Re aaiPharma Inc. Securities Litigation
521 F. Supp. 2d 507 (E.D. North Carolina, 2007)
In Re H & R Block Securities Litigation
527 F. Supp. 2d 922 (W.D. Missouri, 2007)
Frank v. Dana Corp.
525 F. Supp. 2d 922 (N.D. Ohio, 2007)